GLP-1/GIP therapies are reshaping OSA care, but their arrival has exposed a critical guideline gap. Current guidelines lack operational direction on reassessment, multimodal sequencing and therapy discontinuation, risking unverified disease resolution assumptions and unsafe therapy abandonment.